Best Stocks Under $30 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $30.00 (30 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Show:
DigitalBridge Group stock logo

#1 - DigitalBridge Group

NYSE:DBRG
Stock Price:
$16.87 (-$0.29)
P/E Ratio:
34.43
Market Cap:
$2.76 billion
Average Trading Volume:
2.00 million shares
Dividend Yield:
0.23%
<
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$22.08 (30.9% Upside)
DigitalBridge is an infrastructure investment firm specializing in digital infrastructure assets. They provide services to institutional investors. They primarily invest in data centers, cell towers, fiber networks, small cells, and edge infrastructure. DigitalBridge Group, Inc. was founded in 1991 and is headquartered in Boca Raton, Florida with additional offices in Los Angles, California, and New York New York.
Clean Energy Fuels stock logo

#2 - Clean Energy Fuels

NASDAQ:CLNE
Stock Price:
$2.26 (-$0.03)
P/E Ratio:
-5.14
Market Cap:
$504.57 million
Average Trading Volume:
1.63 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.60 (147.8% Upside)
Clean Energy Fuels Corp. provides natural gas as alternative fuels for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.
Harmonic stock logo

#3 - Harmonic

NASDAQ:HLIT
Stock Price:
$9.15 (-$0.28)
P/E Ratio:
12.89
Market Cap:
$1.02 billion
Average Trading Volume:
1.93 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$17.20 (88.0% Upside)
Harmonic Inc., together with its subsidiaries, provides broadband solutions worldwide. The company operates through Broadband and Video segments. The Broadband segment sells broadband access solutions and related services, including cOS software-based broadband access solutions to broadband operators; and cOS central cloud services, a subscription service for cOS customers. The Video segment sells video processing, production, and playout solutions and services to cable operators, and satellite and telco Pay-TV service providers, as well as to broadcast and media, including streaming media companies. Its video processing appliance solutions include network management and application software, and hardware products, such as encoders, video servers, high-density stream processing systems, and edge processors. This segment also provides VOS360 SaaS platform that provides both streaming and channel origination and distribution services; and software-as-a-service (SaaS) solutions, which enables the packaging and delivery of streaming services, including live streaming, VOD, catch-up TV, start-over TV, network-DVR and cloud-DVR services through HTTP streaming to various device along with dynamic and personal ad insertion. The company also provides technical support and professional services, such as maintenance and support, consulting, implementation, integration services, program management, technical design and planning, building and site preparation, integration and equipment installation, end-to-end system testing, and training, as well as SaaS-related support and deployment. It sells its products through its direct sales force, as well as through independent resellers and systems integrators. The company was incorporated in 1988 and is headquartered in San Jose, California.
Zura Bio stock logo

#4 - Zura Bio

NASDAQ:ZURA
Stock Price:
$3.63 (+$0.32)
Market Cap:
$156.43 million
Average Trading Volume:
276,975 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$16.40 (351.8% Upside)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Atlas Energy Solutions stock logo

#5 - Atlas Energy Solutions

NYSE:AESI
Stock Price:
$23.04 (+$0.57)
P/E Ratio:
14.68
Market Cap:
$2.30 billion
Average Trading Volume:
768,558 shares
Dividend Yield:
2.83%
<
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$25.17 (9.2% Upside)
Atlas Energy Solutions Inc. engages in the production, processing, and sale of mesh and sand that are used as a proppant during the well completion process in the Permian Basin of Texas and New Mexico. The company provides transportation and logistics, storage solutions, and contract labor services. It sells its products and services to oil and natural gas exploration and production companies, and oilfield services companies. Atlas Energy Solutions Inc. was founded in 2017 and is headquartered in Austin, Texas.
Quanterix stock logo

#6 - Quanterix

NASDAQ:QTRX
Stock Price:
$15.93 (-$0.11)
P/E Ratio:
-18.52
Market Cap:
$609.32 million
Average Trading Volume:
345,665 shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$32.00 (100.9% Upside)
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Scholar Rock stock logo

#7 - Scholar Rock

NASDAQ:SRRK
Stock Price:
$14.07 (-$0.02)
P/E Ratio:
-7.07
Market Cap:
$1.10 billion
Average Trading Volume:
770,514 shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$25.17 (78.9% Upside)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Kimbell Royalty Partners stock logo

#8 - Kimbell Royalty Partners

NYSE:KRP
Stock Price:
$15.92 (-$0.03)
P/E Ratio:
17.30
Market Cap:
$1.51 billion
Average Trading Volume:
340,491 shares
Dividend Yield:
10.74%
<
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$21.00 (31.9% Upside)
Kimbell Royalty Partners, LP, together with its subsidiaries, engages in acquiring and owning mineral and royalty interests in oil and natural gas properties in the United States. It serves as the general partner of the company. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Dyne Therapeutics stock logo

#9 - Dyne Therapeutics

NASDAQ:DYN
Stock Price:
$24.03 (-$0.95)
P/E Ratio:
-6.10
Market Cap:
$2.07 billion
Average Trading Volume:
1.96 million shares
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$37.43 (55.8% Upside)
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Mirum Pharmaceuticals stock logo

#10 - Mirum Pharmaceuticals

NASDAQ:MIRM
Stock Price:
$24.49 (+$0.47)
P/E Ratio:
-6.17
Market Cap:
$1.15 billion
Average Trading Volume:
553,781 shares
Consensus Rating:
Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$51.70 (111.1% Upside)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Ardelyx stock logo

#11 - Ardelyx

NASDAQ:ARDX
Stock Price:
$6.30 (-$0.13)
P/E Ratio:
-21.00
Market Cap:
$1.47 billion
Average Trading Volume:
6.04 million shares
Consensus Rating:
Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$12.69 (101.4% Upside)
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Integra Resources stock logo

#12 - Integra Resources

NYSEAMERICAN:ITRG
Stock Price:
$0.82 (-$0.01)
P/E Ratio:
-1.52
Market Cap:
$72.71 million
Average Trading Volume:
134,662 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$3.75 (356.2% Upside)
Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
easyJet stock logo

#13 - easyJet

OTCMKTS:ESYJY
Stock Price:
$6.72 (-$0.01)
P/E Ratio:
1.48
Average Trading Volume:
12,717 shares
Dividend Yield:
2.60%
<
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
easyJet plc operates as a low-cost airline carrier in Europe. The company engages in the provision of holiday packages; aircraft trading and leasing activities; development of building projects; financing and insurance business; and tour operator activities. easyJet plc was founded in 1995 and is headquartered in Luton, the United Kingdom.
Uranium Energy stock logo

#14 - Uranium Energy

NYSEAMERICAN:UEC
Stock Price:
$6.67 (+$0.05)
P/E Ratio:
-667.00
Market Cap:
$2.70 billion
Average Trading Volume:
7.77 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.80 (31.9% Upside)
Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing uranium and titanium concentrates in the United States, Canada, and Paraguay. It owns interests in the Palangana mine, Goliad, Burke Hollow, Longhorn, and Salvo projects located in Texas; Anderson, Workman Creek, and Los Cuatros projects situated in Arizona; Dalton Pass and C de Baca project located in New Mexico; Roughrider, Shea Creek, Christie Lake, Horseshoe-Raven, Hidden Bay, Diabase, West Bear, JCU, and other project located in Canada; and Yuty, Oviedo, and Alto Paraná titanium projects in Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. Uranium Energy Corp. was incorporated in 2003 and is headquartered in Corpus Christi, Texas.
Aspen Aerogels stock logo

#15 - Aspen Aerogels

NYSE:ASPN
Stock Price:
$15.96 (-$0.68)
P/E Ratio:
-24.18
Market Cap:
$1.23 billion
Average Trading Volume:
955,868 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$19.00 (19.0% Upside)
Aspen Aerogels, Inc. designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier. The company offers PyroThin thermal barriers for use in lithium-ion batteries in electric vehicles and energy storage industries; Pyrogel XTE that reduces the risk of corrosion under insulation in energy infrastructure operating systems; and Pyrogel HPS for applications within the power generation market. It also offers Pyrogel XTF to provide protection against fire; Cryogel Z for sub-ambient and cryogenic applications in the energy infrastructure market; Spaceloft Subsea for use in pipe-in-pipe applications in offshore oil production; and Cryogel X201, which is used in designing cold systems, such as refrigerated appliances, cold storage equipment, and aerospace systems. The company was founded in 2001 and is headquartered in Northborough, Massachusetts.
Actinium Pharmaceuticals stock logo

#16 - Actinium Pharmaceuticals

NYSEAMERICAN:ATNM
Stock Price:
$6.86 (-$0.20)
P/E Ratio:
-3.75
Market Cap:
$201.68 million
Average Trading Volume:
322,098 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$25.72 (274.9% Upside)
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
DocGo stock logo

#17 - DocGo

NASDAQ:DCGO
Stock Price:
$3.34 (-$0.18)
P/E Ratio:
47.71
Market Cap:
$347.93 million
Average Trading Volume:
1.50 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$10.83 (224.4% Upside)
DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
MAG Silver stock logo

#18 - MAG Silver

NYSEAMERICAN:MAG
Stock Price:
$12.92 (+$0.85)
P/E Ratio:
27.49
Market Cap:
$1.33 billion
Average Trading Volume:
853,780 shares
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$18.25 (41.3% Upside)
MAG Silver Corp. develops and explores for precious metal properties in Canada. It explores for silver, gold, lead, copper, and zinc deposits. The company's flagship property is the 44% owned Juanicipio property located in the Fresnillo District, Zacatecas State, Mexico. MAG Silver Corp. is headquartered in Vancouver, Canada.
Larimar Therapeutics stock logo

#19 - Larimar Therapeutics

NASDAQ:LRMR
Stock Price:
$6.35 (-$0.11)
P/E Ratio:
-7.47
Market Cap:
$405.13 million
Average Trading Volume:
552,134 shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$18.50 (191.3% Upside)
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Entain stock logo

#20 - Entain

OTCMKTS:GMVHF
Stock Price:
$10.07 (-$0.33)
P/E Ratio:
21.57
Average Trading Volume:
2,092 shares
Dividend Yield:
8.81%
<
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Entain Plc operates as a sports-betting and gaming company. The company provides online and multi-channel betting under the Ladbrokes name; street and online betting under the Coral name; online sports betting, casino, and gaming under the Eurobet name; scores, sports information, editorial and social content, and sports focused free-to play games under the 365Scores name; sports betting and games under the SuperSport and BetCity names; online betting under the bwin name; and sports betting, poker, and casino games under the Crystalbet name. It also offers online casino and sports betting under the Optibet name; online bingo under the Gala Bingo; online bingo under the Foxy Bingo name; sportsbetting and gaming under the Sports Interaction and Vistabet names; games under the Nutz and laimz names; game under the boost casino name; online gaming under the Borgata Bingo name; bingo and casino under the Foxy Games name; online bingo, sportsbook, casino, and poker under the betboo; and management software solutions for racing and sportsbooks under the Stadium name. In addition, the company operates sports betting and iGaming under the BetMGM and Sportingbet names; sports betting under the Ladbrokes Australia, TAB NZ, and STS names; Gioco Digitale, a casino platform; Ladbrokes.be, a sports betting outlet; online casino under the NinjaCasino and PartyCasino names; casino and live casino under the Gala Casino name; online poker under the partypoker name; sports under the Neds and Klondaika names; and iGaming platform under the Finnplay name. Entain Plc was incorporated in 2004 and is headquartered in Douglas, Isle of Man.
Triple Flag Precious Metals stock logo

#21 - Triple Flag Precious Metals

NYSE:TFPM
Stock Price:
$16.00 (+$0.16)
P/E Ratio:
84.21
Market Cap:
$3.22 billion
Average Trading Volume:
158,011 shares
Dividend Yield:
1.33%
<
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$17.25 (7.8% Upside)
Triple Flag Precious Metals Corp., a precious-metals-focused streaming and royalty company, engages in acquiring and managing precious metals, streams, royalties and other mineral interests in Australia, Canada, Colombia, Cote d'Ivoire, Honduras, Mexico, Mongolia, Peru, South Africa, the United States, and internationally. The company has a portfolio of streams and royalties providing exposure to gold, silver, nickel, copper, zinc, and lead. It holds a royalty interest in the Beta Hunt mine located in Pert, Wester Australia; the Camino Rojo gold and silver mine located in Mexico; the El Mochito polymetallic mine located in north-western Honduras; and La Colorada polymetallic mine located in Mexico. Triple Flag Precious Metals Corp. was founded in 2016 and is based in Toronto, Canada.
Tempest Therapeutics stock logo

#22 - Tempest Therapeutics

NASDAQ:TPST
Stock Price:
$3.40 (-$0.04)
P/E Ratio:
-1.78
Market Cap:
$75.45 million
Average Trading Volume:
944,775 shares
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$22.25 (554.4% Upside)
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Rani Therapeutics stock logo

#23 - Rani Therapeutics

NASDAQ:RANI
Stock Price:
$6.50 (-$0.49)
P/E Ratio:
-4.89
Market Cap:
$326.04 million
Average Trading Volume:
120,870 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$11.50 (76.9% Upside)
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Canfor stock logo

#24 - Canfor

OTCMKTS:CFPZF
Stock Price:
$10.39 (-$0.07)
P/E Ratio:
8.32
Average Trading Volume:
19,267 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$39.60 (281.1% Upside)
Canfor Corporation operates as an integrated forest products company in the United States, Asia, Canada, Europe, and internationally. It operates in two segments, Lumber, and Pulp and Paper. The company manufactures and sells softwood lumber, remanufactured lumber products, engineered wood, and other lumber-related products, as well as wood chips and pellets; and generates green energy. It also offers dimension lumber products, such as spruce pine fir, southern yellow pine, Douglas fir larch, and Canfor red; specialty lumber products, including Balfour boards, WynnWood board, decking/fascia, lamstock, long lengths, shop/clear, and access mat lumber; and pulp and paper products comprising bleached and unbleached softwood kraft pulp, as well as bleached, colored, and unbleached kraft paper. The company was founded in 1938 and is headquartered in Vancouver, Canada.
Alpine Income Property Trust stock logo

#25 - Alpine Income Property Trust

NYSE:PINE
Stock Price:
$14.89 (-$0.18)
P/E Ratio:
-372.25
Market Cap:
$202.80 million
Average Trading Volume:
53,585 shares
Dividend Yield:
7.11%
<
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$18.35 (23.2% Upside)
Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that seeks to deliver attractive risk-adjusted returns and dependable cash dividends by investing in, owning and operating a portfolio of single tenant net leased properties that are predominately leased to high-quality publicly traded and credit-rated tenants.

More Stock Ideas from MarketBeat